HOME  |   ABOUT US

ABOUT US

ml
OncoStem Diagnostics was founded in 2011 with the vision of developing innovative multimarker prognostic & predictive tests to enable personalized treatment planning for patients with Cancer. OncoStem's mission is to become the leading Oncology Diagnostics Company of the 21st century.

OncoStem's focus is on developing tests to identify patterns of recurrence in various cancers. While most cancer treatment is primarily geared toward preventing cancer recurrence, the knowledge of a patient's risk of recurrence is critical in tailoring personalized therapeutic strategies. OncoStem's first focus has been the development of CanAssist-Breast which identifies risk of recurrence in patients with Hormone Receptor positive Breast Cancer. Similar tests in Oral, Lung, and Colorectal Cancer are under development.

OncoStem's long-term goal is to improve cancer treatment using precision medicine tools. Our tests have been designed and developed with the vision of being used as companion diagnostics to new targeted therapies in the future. OncoStem is currently working towards identifying and characterizing novel drug targets for Breast and Oral Cancer. 

LEADERSHIP

Manjiri Bakre, Ph D

Manjiri Bakre, Ph D

Dr. Bakre –A Cell Biology and Cell Signaling veteran has 18 years experience in research and technology in India, US and Singapore.  She founded OncoStem with the vision of developing and delivering innovative, cost effective and reliable tests for personalized cancer treatment planning.  Previously she has worked in academia at Mt Sinai School of Medicine, NYC and Moores Cancer Center, UCSD and in the industry as well.  Last job at Philips Research involved the development of Point of Care diagnostics. She has won many awards including Young Scientist, paper of the week etc published in Nature Medicine and has multiple patents. 
Chetana Basavaraj, MD (Path)

Chetana Basavaraj, MD (Path)

Dr. Chetana Basavaraj has had immense experience of 18 years as a pathologist. She has worked as a faculty at Dr. Ambedkar Medical College Bangalore followed by a stint of 9 years at Clinigene International Ltd a Biocon company where she was associated with a number of clinical trial projects and proof of concept studies involving histopathology and immunohistochemistry. Her special interest was in Epidermal growth factor receptor and its signaling pathways with IHC analysis in Head & Neck tumors.
Charusheila Ramkumar, MBBS, Ph D

Charusheila Ramkumar, MBBS, Ph D

An experienced Cancer Biologist with 10 years experience in tumor biomarker identification and characterization in the US and India. She has an MBBS degree from MUHS, Nashik and a Ph D from UMass Medical School, Worcester, MA. She has published in international journals including Nature Communications and Cancer Research and won the Zelda Haidak memorial award for outstanding graduate student. 
Praveen B P, MBA

Praveen B P, MBA

Diligent and result oriented professional with more than 18 years of experience in Pharma/Diagnostic services through sales, business development and marketing especially in Oncology. Formerly he was associated with Oncquest Laboratories Ltd, Digene,SRL Laboratories and Ferring Pharmaceuticals Ltd.

Scientific Advisors

Investment Advisors 

Investors

Investors


OncoStem Diagnostics funded by Artiman Ventures. Artiman is an early-stage Silicon Valley-based venture fund that invests in white space companies and also this Venture capital firm provides a pathway to Silicon Valley for aspiring student entrepreneurs with backgrounds in Biology, Economics, Technology, and the Arts. For more details click here.

Our Science

OncoStem is focused on developing innovative prognostic and predictive solutions for various types of Cancers. Our approach involves integrating the molecular signature of the disease with clinicopathological parameters that are time-tested in prognostic evaluation of cancer. We use our expertise in tumor biology to create actionable solutions that assist physicians in developing optimal therapeutic programs for their patients. We utilize gold-standard protein or gene expression techniques in our assays and combine them with a deep learning approach that enhances our knowledge of cancer. Our flagship test, CanAssist-Breast is focused on the risk of recurrence prediction in Breast Cancer. We are developing similar tests for Head & Neck and Colon Cancer. 

Accreditations and Licences

 
Certificate of CE (IVD) notification, Order No. MC 5104-2016

ISO 13485:2003 , Certificate No. 11287367.PDWS

NABL – ISO 15189:2012, Certificate No. M-0893

NABH – Certificate No. MLP-2015-0056